AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Viking Therapeutics, Inc.
Video analysis: VKTX
All videosNo video analysis for this stock yet. Request one from our team.
News: VKTX
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue from its central nervous system treatments. Viking Therapeutics remains a clinical-stage player with significant potential in the high-demand obesity and metabolic disease markets.
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.
Viking Therapeutics is studying its weight-loss drug candidate in phase 3 trials. Today Eli Lilly and Novo Nordisk dominate the market, but high demand suggests there's room for additional players.
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Viking Therapeutics, Inc. (VKTX) closed at $32.7 in the latest trading session, marking a -2.91% move from the prior day.
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.
Viking Therapeutics has significant upside potential based on Wall Street targets. VK2735's dual-formulation strategy could differentiate it in a crowded obesity drug market, but it faces major risks, including strong competition and safety concerns with the oral formulation.
Jupiter Topco LLC Makes New Investment in Viking Therapeutics, Inc. $VKTX
Jupiter Topco LLC acquired a new stake in Viking Therapeutics, Inc. (NASDAQ: VKTX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 45,700 shares of the biotechnology company's stock, valued at approximately $1,783,000. Other hedge funds and other institutional investors
Similar companies
-
Crinetics Pharmaceuticals, Inc.
CRNX
·
NASDAQ
Compare
-
Kymera Therapeutics, Inc.
KYMR
·
NASDAQ
Compare
-
Immunovant, Inc.
IMVT
·
NASDAQ
Compare
-
NewAmsterdam Pharma Company N.V.
NAMS
·
NASDAQ
Compare
-
Praxis Precision Medicines, Inc.
PRAX
·
NASDAQ
Compare
-
Ascentage Pharma Group International
AAPG
·
NASDAQ
Compare